Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Ascentage Pharma Group International Equity-to-Asset?
Ascentage Pharma Group InternationalASPHF 62 Equity-to-Asset is 0.33 as of Dec. 2025, which is 175% above its 10-year median of 0.12. GuruFocus rates ASPHF with a GF Scoreâ„¢ of 62/100 and a GF Valueâ„¢ of $7.50 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,413 Biotechnology companies, Ascentage Pharma Group International ranks worse than 77.42% on this metric.
ASPHF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.82 Med: 0.12 Max: 0.74
Current: 0.33
During the past 10 years, the highest Equity to Asset Ratio of Ascentage Pharma Group International was 0.74. The lowest was -0.82. And the median was 0.12.
ASPHF's Equity-to-Asset is ranked worse than 77.42% of 1413
companies
in the Biotechnology industry
Industry Median: 0.68
vs ASPHF: 0.33
Ascentage Pharma Group International (OTCPK:ASPHF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Ascentage Pharma Group International Equity-to-Asset Related Terms
Ascentage Pharma Group International Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International Equity-to-Asset Chart
ASPHF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Ascentage Pharma Group International's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Ascentage Pharma Group International's Equity-to-Asset falls into.
Ascentage Pharma Group International Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International (ASPHF) has a Equity-to-Asset of 0.33 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ascentage Pharma Group International and its competitors. This is 175% above median its historical median of 0.12. According to the industry distribution chart, Ascentage Pharma Group International ranks #1094 out of 1413 companies in the Biotechnology industry, placing it in the top 77.4%.
Is Ascentage Pharma Group International's Equity-to-Asset too high?
Ascentage Pharma Group International's current Equity-to-Asset of 0.33 is 175% above median its 10-year median of 0.12. The Biotechnology industry median Equity-to-Asset is 0.68. Ascentage Pharma Group International's value of 0.33 is 51.5% below this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #1094 out of 1413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascentage Pharma Group International has a GF Scoreâ„¢ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #1094 out of 1413 companies for Equity-to-Asset. This places Ascentage Pharma Group International in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Ascentage Pharma Group International's value of 0.33 is 51.5% below this benchmark. While the company's 10-year median is 0.12 vs. the industry median of 0.68, Ascentage Pharma Group International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current Equity-to-Asset of 0.33 is 51.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current Equity-to-Asset is 0.33, which is 175% above median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $7.50, compared to a current price of $4.53 — trading 39.6% below its estimated fair value. The current Equity-to-Asset is 0.33, which is 175% above median its 10-year median of 0.12 and 51.5% below the Biotechnology industry median of 0.68. Ascentage Pharma Group International's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Equity-to-Asset is 0.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $4.53 is trading 39.6% below its estimated GF Value™ of $7.50.
GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.
Key valuation signals for ASPHF:
Equity-to-Asset: 0.33 (175% above median its 10-year median of 0.12)
GF Value™: $7.50 vs. price of $4.53 (39.6% below fair value)
Industry Position: 51.5% below the Biotechnology median (#1094 of 1413)
No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
62GF Score
Get the complete analysis for ASPHF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASPHF has been successfully added to your 
